

**AMENDMENTS TO THE CLAIMS**

Claims 1-66 (Canceled)

Claim 67 (New): A composition of highly pure polyclonal Th1 cells generated by a method comprising:

- (a) collecting T cells from a subject; and
- (b) activating the T cells a minimum of 3 times at 2-4 day intervals with one or more mitogenic antibodies immobilized on microbeads or nanobeads, whereby a highly pure population of polyclonal Th1 cells are produced.

Claim 68 (New): The composition of claim 67, wherein the mitogenic antibodies are anti-CD3 and anti-CD28 monoclonal antibodies.

Claim 69 (New): The composition of claim 67, wherein the polyclonal Th1 cells are activated.

Claim 70 (New): A method of treating a disease, comprising infusing the composition of claim 67 into a subject with symptoms of a disease, wherein the disease is characterized by suppression of the cellular immune response, by over-expression of the humoral immune response, excess Th2 activity or a lack or decreased Th1 activity.

Claim 71 (New): The method of claim 70, wherein the disease is selected from the group consisting of cancer, infectious diseases and allergic diseases.

Claim 72 (New): The method of claim 71, wherein the subject has cancer.